Repurposing Safe Drugs to Direct DNA Repair in CRISPR Editing

Study Background and Research Question

Genome editing technologies, particularly CRISPR-Cas systems, have revolutionized the ability to introduce targeted DNA double-strand breaks (DSBs) at precise genomic locations. However, the cellular mechanisms responsible for repairing these breaks—mainly non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR)—often compete and can yield unpredictable outcomes, such as insertions, deletions, or precise edits. The type of repair pathway engaged directly impacts the fidelity and utility of genome editing, which is critical for disease modeling, gene therapy, and synthetic lethality approaches in cancer treatment. The referenced study addressed a central question: can clinically safe, FDA-approved drugs be systematically repurposed to modulate cellular DNA repair pathway choice during CRISPR genome editing in human cells?

Key Innovation from the Reference Study

The key innovation lies in the large-scale, unbiased screening of over 7,000 FDA-approved drug conditions to identify small molecules that can selectively enhance or inhibit specific DNA repair pathways following CRISPR-induced DSBs. Unlike previous approaches that focused on a handful of pathway inhibitors, this work comprehensively mapped the capacity of existing drugs to influence genome editing outcomes by shifting the balance among NHEJ, MMEJ, and HDR. This provides a new toolkit for programmable repair pathway manipulation with compounds already vetted for clinical safety, significantly lowering translational barriers for both research and therapeutic applications.

Methods and Experimental Design Insights

The authors utilized human induced pluripotent stem cells (hiPSCs) engineered to express a doxycycline-inducible Cas9 (iCRISPR system), enabling precise temporal control of DSB induction. During drug treatment, cells were subjected to CRISPR editing at the FRMD7 locus, and survival was quantified via resazurin fluorescence. To delineate repair pathway usage, DNA was extracted and subjected to high-throughput Illumina sequencing, with mutational outcomes assigned to NHEJ, MMEJ, or HDR based on the nature of the sequence changes. Each drug condition was tested in a single replicate due to the scale (n = 7,240). The workflow allowed for direct measurement of how each compound affected cell survival and the spectrum of repair outcomes, generating a detailed landscape of drug-induced pathway modulation.

Core Findings and Why They Matter

The study found that multiple clinically approved drugs can significantly shift DNA repair pathway usage following CRISPR-induced DSBs. Some compounds enhanced the frequency of precise HDR events, while others suppressed NHEJ or MMEJ, leading to altered indel profiles or increased gene knock-in efficiency. Notably, the manipulation of repair pathway choice was not merely academic; it translated to improved precision in introducing desired edits and provided new avenues for synthetic lethality strategies in cells with specific DNA repair deficiencies. For example, silencing estrogen receptor 2 (ESR2) synergized with NHEJ inhibition to yield a mean 4.6-fold increase in HDR, highlighting the potential for combinatorial approaches. Additionally, drugs that induced synthetic lethality in the context of blocked NHEJ or HDR were identified as candidates for precision cancer therapy. The ability to fine-tune repair outcomes using drugs already in clinical use accelerates the path toward safer and more effective gene therapies and disease models.

Comparison with Existing Internal Articles

Several internal reviews have explored related concepts. The article "Dantrolene Sodium Salt: Mechanistic Power and Translation" discusses how high-purity ryanodine receptor antagonists such as dantrolene sodium salt enable advanced control of intracellular calcium signaling in both disease modeling and genome editing. This mechanistic insight is complementary, as calcium signaling is intricately linked to DNA damage responses and repair pathway choice. The review "Dantrolene Sodium Salt: Ryanodine Receptor Antagonist in Research" further highlights the role of precise calcium modulation in optimizing genome editing workflows. Meanwhile, "Drug Repurposing for DNA Repair Pathway Control in CRISPR Editing" offers a broad survey of small molecule modulators for DSB repair, echoing the comprehensive screening approach of the present reference. Collectively, these resources underscore the value of integrating chemical modulation of calcium and DNA repair processes for next-generation editing and disease modeling.

Limitations and Transferability

While the screening encompassed a vast array of drug conditions, only one replicate per condition was tested, which may limit statistical power for weaker effects. The use of a single hiPSC line and genomic locus (FRMD7) raises questions about generalizability to other cell types or target sites, especially in differentiated cells or in vivo contexts. Furthermore, the observed effects on repair pathway choice may be influenced by off-target drug actions unrelated to DNA repair. Despite these caveats, the identification of robust modulators among clinically approved drugs provides a valuable starting point for further validation and optimization in more complex systems and disease models.

Protocol Parameters

• CRISPR-Cas9 induction: Use doxycycline to temporally control Cas9 expression in hiPSC models, enabling synchronized DSB induction during drug treatment.
• Drug treatment timing: Apply candidate pathway modulators during and immediately after genome editing to maximize influence on DSB repair outcome.
• Cell survival quantification: Employ resazurin fluorescence assays post-editing to assess cytotoxicity and synthetic lethality in response to drug-DSB interactions.
• Repair pathway assignment: Use high-throughput sequencing and indel/deletion profiling to assign editing outcomes to NHEJ, MMEJ, or HDR, adapting the pipeline for different cell types and loci as needed.
• Validation step: For candidate drugs, perform secondary screens or dose-response assays in triplicate to confirm reproducibility across biological replicates.

Why this cross-domain matters, maturity, and limitations

Bridging drug repurposing in genome editing with synthetic lethality and precision medicine is highly relevant for oncology and gene therapy. The maturity of this approach is underpinned by the clinical safety of the screened drug library, yet practical implementation in diverse cell types and disease contexts will require additional validation. While the evidence supports proof-of-concept for programmable DNA repair modulation, translation to patient-derived cells or in vivo settings is still an active area of investigation. The study sets the stage for targeted, small molecule-based enhancement of editing fidelity and therapeutic index, but caution is warranted regarding off-target effects and context-dependence.

Outlook

The reference study outlines a powerful paradigm for using clinically safe drugs to steer DNA repair pathway choice during CRISPR genome editing, with direct implications for disease modeling, cell engineering, and cancer therapy. By enabling finer control of indel and precise repair outcomes, this strategy expands the toolbox for researchers and clinicians aiming to optimize genome editing fidelity and exploit synthetic lethality in cancer. Continued work will refine these tools and determine their broader applicability across disease models and therapeutic settings.

Research Support Resources

Researchers seeking to modulate intracellular calcium signaling—which intersects with DNA repair and cell survival pathways—can incorporate Dantrolene, sodium salt (SKU B6329), a high-purity ryanodine receptor antagonist from APExBIO, into their workflows. Its potency and specificity for ryanodine receptors support advanced studies in calcium signaling modulation and synthetic lethality. For additional mechanistic background and protocol optimization, the article "Dantrolene, sodium salt: A Benchmark Ryanodine Receptor Antagonist" offers detailed biochemical rationale and usage guidelines.